Disclosed herein are glucosyltransferases with modified amino acid sequences. Such engineered enzymes exhibit improved alpha-glucan product yields and/or lower leucrose yields, for example. Further disclosed are reactions and methods in which engineered glucosyltransferases are used to produce alpha-glucan.

The purpose of the present invention is to provide a steviol glycoside hexose transferase, and a method for producing a steviol glycoside that contains glucose and/or rhamnose using said enzyme. The present invention provides a steviol glycoside hexose transferase, and a method for producing a steviol glycoside that contains glucose and/or rhamnose using said enzyme. The present invention also provides a transformant into which a steviol glycoside hexose transferase gene has been introduced, and a method for preparing said transformant.

Compositions for and methods of manufacturing a fucosylated cell population are provided. The method may include expansion of the cells and/or cryopreservation of the cells under conditions that retain optimum levels of cell surface fucosylation.

Transgenic plants with blue flower color, or their inbred or outbred progeny, or their propagules, partial plant bodies, tissues or cells, are provided. A buckwheat-derived C-glucosyltransferase (CGT) gene or its homolog is transferred into a host plant to cause delphinidin-type anthocyanins and flavone mono-C-glycosides to be copresent in the plant cells.

The present invention provides nucleic acids, vectors, host cells and methods for production of fructosyltransferase from Aspergillus japonicus. The invention represents an advancement in the field of genetic engineering and provides methods for obtaining high yield of a novel recombinant fructosyltransferase encoded by ft gene of Aspergillus japonicus as a secreted protein.

The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

A batch fermentation process ferments a starch hydrolysate containing 80-98 weight percent of glucose based on total carbohydrate and 0.3-5% weight percent of isomaltose based on total carbohydrate to a fermentation product. A fermentation broth is formed containing a first portion of a total amount of the starch hydrolysate so that the fermentation broth has an initial glucose concentration of at least about 50 g/L. Fermentaion is carried out until the fermentation broth contains 30 g/L or less of glucose. An effective amount of at least one active enzyme that converts isomaltose into glucose is adding to the fermentation broth. Then the remaining portion of the total amount of starch hydrolysate is fed into the fermentation broth to maintain a glucose concentration of from about 5 to about 15 g/L in the fermentation broth throughout the feeding step. The final fermentation broth containing the fermentation product is then produced.

Described herein are devices and methods for increasing the production of steviol glycosides, which have industrial and economic value. The steviol glycosides produced by the devices and methods disclosed herein do not require the ultra purification that is common in conventional or commercial methods and do not have a bitter aftertaste, making them better suited as flavor-enhancing additives to food, pharmaceutical, and nutritional supplement products.

The present invention relates generally to the identification novel UDP-glucosyltransferases enzymes having specific activity towards cannabinoid compounds. The present invention further relates generally to the use of novel UGT enzymes having specific activity towards cannabinoid compounds to generate water-soluble cannabinoid glycoside compounds.

The disclosure discloses a method for efficient biosynthesis of Reb D by glycosyltransferase, belonging to the field of biocatalytic synthesis. According to the disclosure, a glycosyltransferase having an activity to catalyze synthesis of Reb D from Reb A is obtained, and a mutant YojK-I241T/G327N with high catalytic activity is obtained through directed evolution. The glycosyltransferase mutant YojK-I241T/G327N and a sucrose synthase AtSuSy derived from Arabidopsis thaliana are used for constructing a coupling reaction to realize efficient catalytic synthesis of Reb D with Reb A as a substrate. The reaction is carried out by using 19.32 g/L (20 mmol/L) of Reb A as the substrate for 15 h to efficiently synthesize 20.59 g/L of Reb D, and the yield of Reb D reaches 91.29%, which provides an efficient and green new pathway for production of Reb D.